Home » Topics » Disease categories and therapies » Dermatologic

Dermatologic
RSS

Connetics submits NDA for Actiza

Dec. 30, 2003

PVAC development for psoriasis discontinued

Dec. 30, 2003

Disappointing results for HuMax-CD4 in phase IIb psoriasis trial

Dec. 17, 2003

Finacea approved in E.U. as topical treatment of papulopustular rosacea

Dec. 17, 2003

Fujisawa launches pediatric Protopic in Japan

Dec. 16, 2003

OrCel achieves primary and secondary endpoints in venous leg ulcer study

Dec. 15, 2003

Novactyl seeks licensing partner for PCL-016

Dec. 11, 2003

Nippon Shinyaku presents novel antipruritic agents

Dec. 9, 2003

A role for IL-15 in the pathogenesis of psoriasis

Dec. 5, 2003

Melanotan reduces sunburn injury by increasing melanin density in clinical trial

Dec. 3, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...